CADLCandel Therapeutics, Inc.Running, no new patients
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Non Small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 90 (final count)
- Started
- Oct 13, 2020
- Main results expected
- Dec 31, 2024
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Response rate
Measured over: 12 months
Safety graded by CTCAE version 5.0
Measured over: 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-31, no fading
Raw record changes
- none yet
Trial ID NCT04495153 · record last updated 2026-11-05 · checked 2026-11-09 15:42 UTC